新型抗前列腺癌药物ODM-201的研究进展  

Research of new anti-prostate cancer drug ODM-201

作　　者：黄晨超 包旗旗 张荣玉 周金明 HUANG Chenchao;BAO Qiqi;ZHANG Rongyu;ZHOU Jinming(Drug Discovery and Innovation Center&College of Chemistry and Life Sciences,Zhejiang Normal University,Jinhua 321004,China)

机构地区：[1]浙江师范大学化学与生命科学学院&现代制药创新研究中心,浙江金华321004

出　　处：《药学研究》2021年第6期351-358,370,共9页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.22077115、81672559)。

摘　　要：前列腺癌(prostate cancer,PC)是男性泌尿生殖系统最常见的恶性肿瘤,患者在接受雄激素剥夺疗法(androgen deprivation therapy,ADT)后,病情往往会继续发展至去势抵抗性阶段,危及生命。抗雄激素药物是治疗去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)最重要且有效的方法。ODM-201具有良好的体外抗细胞增殖活性和抗肿瘤活性,经过长期的临床试验目前已经获得美国食品药品监督管理局(FDA)批准,是极具前景的第二代抗雄激素药物。因此对ODM-201的药学研究具有重要意义,本文就其作用机理、临床研究、合成工艺研究等方面进行了综述。Prostate cancer is the most common male malignant tumor of the male genitourinary system.After the period of androgen deprivation therapy(ADT),the disease will often develop to the lethal castration-resistant prostate cancer(CRPC).Antiandrogens are still the most important agents in treatment of CRPC.ODM-201 has good anti-cell proliferation activity in vitro and anti-tumor activity.After long-term clinical trials,it has been approved by the FDA as a promising second-generation anti-androgen drug.Therefore,it is of great significance to perform the pharmaceutical research of ODM-201.This review demonstrated the mechanism of action,clinical research,and synthesis technology etc of ODM-201.

关 键 词：去势抵抗性前列腺癌 抗雄激素药物 ODM-201 临床 机理 合成工艺 

分 类 号：R979.1[医药卫生—药品]